{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:20:24Z","timestamp":1785892824311,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The impact of COVID-19 across health services, including treatment services for people who use drugs, is emerging but likely to have a high impact. Treatment services for people who use drugs provide essential treatment services including opiate agonist treatment and needle syringe programmes alongside other important treatment programmes across all substance types including withdrawal and counselling services. Drug and alcohol hospital consultation-liaison clinicians support emergency departments and other services provided in hospital settings in efficiently managing patients who use drugs and present with other health problems.<\/jats:p><jats:p>COVID-19 will impact on staff availability for work due to illness. Patients may require home isolation and quarantine periods. Ensuring ongoing supply of opiate treatment during these periods will require significant changes to how treatment is provided. The use of monthly depot buprenorphine as well as moving from a framework of supervised dosing will be required for patients on sublingual buprenorphine and methadone. Ensuring ready access to take-home naloxone for patients is crucial to reduce overdose risks. Delivery of methadone and buprenorphine to the homes of people with confirmed COVID-19 infections is likely to need to occur to support home isolation.<\/jats:p><jats:p>People who use drugs are likely to be more vulnerable during the COVID-19 epidemic, due to poorer health literacy and stigma and discrimination towards this group. People who use drugs may prioritise drug use above other health concerns. Adequate supply of clean injecting equipment is important to prevent outbreaks of blood-borne viruses. Opiate users may misinterpret SARS-CoV2 symptoms as opiate withdrawal and manage this by using opioids. Ensuring people who use drugs have access to drug treatment as well as access to screening and testing for SARS-CoV2 where this is indicated is important.<\/jats:p>","DOI":"10.1186\/s12954-020-00370-7","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T11:03:42Z","timestamp":1588763022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":214,"title":["Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-5966","authenticated-orcid":false,"given":"Adrian","family":"Dunlop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddhima","family":"Lokuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Saul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Ezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"370_CR1","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.","DOI":"10.1016\/S0140-6736(20)30566-3"},{"issue":"2","key":"370_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.24171\/j.phrp.2020.11.2.03","volume":"11","author":"MA Khafaie","year":"2020","unstructured":"Khafaie MA, Rahim F. Cross-country comparison of case fatality rates of COVID-19\/SARS-COV-2. Osong Public Health and Research Perspectives. 2020;11(2):74.","journal-title":"Osong Public Health and Research Perspectives."},{"key":"370_CR3","volume-title":"Report 4: Severity of 2019-novel coronavirus (nCoV)","author":"I Dorigatti","year":"2020","unstructured":"Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: Severity of 2019-novel coronavirus (nCoV). London: Imperial College London; 2020."},{"issue":"10159","key":"370_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GA Roth","year":"2018","unstructured":"Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1736\u201388.","journal-title":"The Lancet."},{"issue":"12","key":"370_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"The Lancet Psychiatry."},{"issue":"9810","key":"370_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(11)61138-0","volume":"379","author":"L Degenhardt","year":"2012","unstructured":"Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet. 2012;379(9810):55\u201370.","journal-title":"The Lancet."},{"issue":"12","key":"370_CR7","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health. 2017;5(12):e1192\u2013e207.","journal-title":"The Lancet Global Health."},{"key":"370_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugalcdep.2018.01.008","volume":"186","author":"L-T Wu","year":"2018","unstructured":"Wu L-T, Ghitza UE, Zhu H, Spratt S, Swartz M, Mannelli P. Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes. Drug and alcohol dependence. 2018;186:86\u201393.","journal-title":"Drug and alcohol dependence."},{"issue":"2","key":"370_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF03391702","volume":"35","author":"MT Schulte","year":"2013","unstructured":"Schulte MT, Hser Y-I. Substance use and associated health conditions throughout the lifespan. Public health reviews. 2013;35(2):3.","journal-title":"Public health reviews."},{"key":"370_CR10","unstructured":"Australian Institute of Health and Welfare. Alcohol, tobacco & other drugs in Australia: People experiencing homelessness: AIHW; 2020 [Available from: https:\/\/www.aihw.gov.au\/reports\/alcohol\/alcohol-tobacco-other-drugs-australia\/contents\/priority-populations\/homeless-people."},{"issue":"4","key":"370_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0955-3959(01)00097-4","volume":"12","author":"J Neale","year":"2001","unstructured":"Neale J. Homelessness amongst drug users: a double jeopardy explored. International journal of drug policy. 2001;12(4):353\u201369.","journal-title":"International journal of drug policy."},{"issue":"10","key":"370_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/add.13877","volume":"112","author":"S Fazel","year":"2017","unstructured":"Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725\u201339.","journal-title":"Addiction."},{"issue":"1-2","key":"370_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC Van Boekel","year":"2013","unstructured":"Van Boekel LC, Brouwers EP, Van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug and alcohol dependence. 2013;131(1-2):23\u201335.","journal-title":"Drug and alcohol dependence."},{"key":"370_CR14","volume-title":"World Health Organization model list of essential medicines: 21st list 2019","author":"Organization WH","year":"2019","unstructured":"Organization WH. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization; 2019."},{"key":"370_CR15","doi-asserted-by":"crossref","unstructured":"Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. The Lancet Public Health. 2020.","DOI":"10.1016\/S2468-2667(20)30053-0"},{"issue":"3","key":"370_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1183\/13993003.01967-2015","volume":"48","author":"NT Vozoris","year":"2016","unstructured":"Vozoris NT, Wang X, Fischer HD, Bell CM, O'Donnell DE, Austin PC, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. European Respiratory Journal. 2016;48(3):683\u201393.","journal-title":"European Respiratory Journal."},{"issue":"5","key":"370_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MCP.0000000000000513","volume":"24","author":"RL Ramirez III","year":"2018","unstructured":"Ramirez RL III, Perez VDJ, Zamanian RT. Methamphetamine and the risk of pulmonary arterial hypertension. Current opinion in pulmonary medicine. 2018;24(5):416.","journal-title":"Current opinion in pulmonary medicine."},{"issue":"18","key":"370_CR18","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","volume":"18","author":"M Dematteis","year":"2017","unstructured":"Dematteis M, Auriacombe M, D\u2019Agnone O, Somaini L, Szerman N, Littlewood R, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert opinion on pharmacotherapy. 2017;18(18):1987\u201399.","journal-title":"Expert opinion on pharmacotherapy."},{"key":"370_CR19","unstructured":"Centre for Population Health. NSW clinical guidelines: treatment of opioid dependence GL2018_019. North Sydney: NSW Ministry of Health; 2018."},{"key":"370_CR20","unstructured":"Internatoinal Netowrk of People who Use Drugs. COVID-19 crisis: harm reduction resources for people who use drugs: INPUD; 2020 [Available from: https:\/\/www.inpud.net\/en\/covid-19-crisis-harm-reduction-resources-people-who-use-drugs."},{"issue":"6","key":"370_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/alcalc\/agn073","volume":"43","author":"P Wu","year":"2008","unstructured":"Wu P, Liu X, Fang Y, Fan B, Fuller CJ, Guan Z, et al. Alcohol abuse\/dependence symptoms among hospital employees exposed to a SARS outbreak. Alcohol Alcohol. 2008;43(6):706\u201312.","journal-title":"Alcohol Alcohol."},{"key":"370_CR22","doi-asserted-by":"publisher","DOI":"10.3320\/978-0-932627-51-3","volume-title":"Responding to community outrage: strategies for effective risk communication: AIHA","author":"PM Sandman","year":"1993","unstructured":"Sandman PM. Responding to community outrage: strategies for effective risk communication: AIHA; 1993."},{"issue":"10","key":"370_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5694\/mja2.50602","volume":"212","author":"CB Dalton","year":"2020","unstructured":"Dalton CB, Corbett SJ, Katelaris AL. Pre-emptive low cost social distancing and enhanced hygiene implemented before local COVID-19 transmission could decrease the number and severity of cases. The Medical Journal of Australia. 2020;212(10):1.","journal-title":"The Medical Journal of Australia."},{"issue":"2-3","key":"370_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","volume":"118","author":"B Larance","year":"2011","unstructured":"Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug and alcohol dependence. 2011;118(2-3):265\u201373.","journal-title":"Drug and alcohol dependence."},{"issue":"1","key":"370_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.285.1.39","volume":"285","author":"M Auriacombe","year":"2001","unstructured":"Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. Jama. 2001;285(1):45.","journal-title":"Jama"},{"key":"370_CR26","volume-title":"Clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence","author":"N Lintzeris","year":"2019","unstructured":"Lintzeris N, Dunlop A, Masters D. Clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence. NSW Ministry of Health: Sydney; 2019."},{"key":"370_CR27","unstructured":"Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, et al. Report 3: transmissibility of 2019-nCoV. Imperial College London. 2020."},{"key":"370_CR28","doi-asserted-by":"crossref","unstructured":"Dunlap E, Golub A. Drug markets during the Katrina disaster. Disaster prevention and management: an international journal. 2011.","DOI":"10.1108\/09653561111141709"},{"issue":"2","key":"370_CR29","doi-asserted-by":"publisher","first-page":"e141-e","DOI":"10.4172\/2375-4435.1000141","volume":"4","author":"E Dunlap","year":"2016","unstructured":"Dunlap E, Townes J. Violence and the illicit drug market: before during and after disasters. Sociology and criminology open access. 2016;4(2):e141-e.","journal-title":"Sociology and criminology open access."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00370-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-020-00370-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00370-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:30:29Z","timestamp":1620261029000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00370-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00370-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"29 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no data relating to individuals in the text; therefore, institutional ethics committee clearance has not been sought regarding this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.D. reports grants from Braeburn\/Camurus AB, to conduct clinical studies with buprenorphine products and travel support to Hunter New England Local Health District, which employs A.D. A.D is an investigator on an Indivior-funded study of buprenorphine products. A.D has serviced on an advisory board for Mundipharma.P.H. reports grants from Braeburn\/Camurus AB to conduct clinical studies with buprenorphine products to Sydney Local Health District, which employs P.H.N.L. has received funding from Braeburn, Camurus and Indivior to conduct clinical studies with buprenorphine products and has served on advisory boards for Indivior and Mundipharma.A.D., B.L., D.M., M.S., P.S. and M.H. are employed by Hunter New England Local Health District, a public health service funded by the NSW Ministry of Health.P.H. is employed by Sydney Local Health District, a public health service funded by the NSW Ministry of Health.N.L. is employed by Sydney South East Local Health District, a public health service funded by the NSW Ministry of Health.There are no other author interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}